1. Home
  2. HUIZ vs APRE Comparison

HUIZ vs APRE Comparison

Compare HUIZ & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huize Holding Limited

HUIZ

Huize Holding Limited

N/A

Current Price

$1.34

Market Cap

13.4M

Sector

Finance

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.73

Market Cap

10.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HUIZ
APRE
Founded
2006
2006
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
10.8M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
HUIZ
APRE
Price
$1.34
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.73
AVG Volume (30 Days)
31.0K
★ 143.1K
Earning Date
08-20-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.22
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.48
N/A
Revenue Next Year
$6.59
N/A
P/E Ratio
$7.81
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$0.55
52 Week High
$4.16
$1.69

Technical Indicators

Market Signals
Indicator
HUIZ
APRE
Relative Strength Index (RSI) 44.91 47.94
Support Level $1.17 $0.70
Resistance Level $1.55 $0.79
Average True Range (ATR) 0.08 0.05
MACD -0.02 -0.00
Stochastic Oscillator 17.07 33.94

Price Performance

Historical Comparison
HUIZ
APRE

About HUIZ Huize Holding Limited

Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: